ReviewFrontiers in oncology2015
Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet.
Review in Frontiers in oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Review
- Precision Medicine in Colorectal Cancer: Targeted Therapies and Biomarker Insights.Current cancer drug targets · 2026Review
- Dissecting the MAPK signaling landscape in malignant melanoma: from BRAF and NRAS mutations to precision combination therapies.Frontiers in cell and developmental biology · 2025Review
- Article
- Bioinformatics analysis of rheumatoid arthritis tissues identifies genes and potential drugs that are expressed specifically.Scientific reports · 2023Article
- Review
- Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines.SLAS discovery : advancing life sciences R & D · 2021Article
- Therapeutic Effects of Naringin in Rheumatoid Arthritis: Network Pharmacology and Experimental Validation.Frontiers in pharmacology · 2021Article
- miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanoma.PloS one · 2020Article
- Systematic evaluation of the microRNAome through miR-CATCHv2.0 identifies positive and negative regulators ofRNA biology · 2019Article
- A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells.Molecular cancer therapeutics · 2018Article
- A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC.PloS one · 2018Article
- The anti-apoptotic BAG3 protein is involved in BRAF inhibitor resistance in melanoma cells.Oncotarget · 2017Article
- Etlingera elatior Extract promotes cell death in B16 melanoma cells via down-regulation of ERK and Akt signaling pathways.BMC complementary and alternative medicine · 2017Article
- Structure-Guided Strategy for the Development of Potent Bivalent ERK Inhibitors.ACS medicinal chemistry letters · 2017Article
- Rational design of non-resistant targeted cancer therapies.Scientific reports · 2017Article
- Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells.Oncotarget · 2017Article
- Naringin enhances osteogenic differentiation through the activation of ERK signaling in human bone marrow mesenchymal stem cells.Iranian journal of basic medical sciences · 2017Article
- Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.Journal of clinical pharmacology · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.